The pharmaceutical landscape for autoimmune and inflammatory treatments is currently dominated by the rise of Janus Kinase (JAK) inhibitors, with Baricitinib Market at the forefront. As of 2025, the Baricitinib market has transitioned from a specialized rheumatoid arthritis treatment into a multi-indication blockbuster therapy. https://livepositively.com/unlocking-value-pricing-regulatory-landscape-and-future-forecast-for-the-ocular-bromfenac-market-2025-2032/